Article Text

other Versions

PDF
Randomised clinical trial
Varenicline may reduce negative affect while aiding smoking cessation
  1. J Taylor Hays
  1. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to: Dr J Taylor Hays, Department of Internal Medicine, Mayo Clinic, 200 1st Street, Rochester, Minnesota 55905, USA; hays.taylor{at}mayo.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science.

Context

Cigarette smoking remains the most important cause of preventable morbidity and premature mortality, with projected annual tobacco-attributable deaths worldwide estimated to reach nearly 6.5 million by 2015.1 The most effective treatment for tobacco dependence is combined behavioural and pharmacological therapy, which is widely available yet underemployed. Most attempts to quit smoking are still unaided, and surveys suggest that pharmacological treatment is often not used optimally.2 Even when used effectively, most attempts to quit smoking with pharmacological support still result in relapse …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.